Harbin Pharmaceutical Group
| Harbin Pharmaceutical Group Co., Ltd. | |||||||
|---|---|---|---|---|---|---|---|
| Simplified Chinese | 哈药集团股份有限公司 | ||||||
| Traditional Chinese | 哈藥集團股份有限公司 | ||||||
| Literal meaning | Harbin Pharmaceutical Group, Company Limited by Shares | ||||||
| |||||||
Harbin Pharmaceutical Group Co., Ltd. (SSE: 600664) is China's second-biggest drug maker by market value.[1] The major shareholder of the company was Chinese: 哈药集团有限公司 for 47.06% stake (as at 30 June 2016), literally have the same English name with the listed subsidiary, as the listed subsidiary missed the word "Joint-Stock / Shares" (Chinese: 股份) in its English official name.
Business
Harbin Pharmaceutical is engaged in the research, development, manufacture and sale of pharmaceutical products. The Company primarily offers antibiotics, Chinese patent medicines, over-the-counter (OTC) medicines, healthcare products and synthesized preparations, among others.
During the year ended December 31, 2007, the Company obtained approximately 73% and 14% of its total revenue from the sale of western medicines and traditional Chinese medicines, respectively. As of December 31, 2007, the Company had two subsidiaries/associates: one specializes in manufacturing oral solutions, while the other is engaged in the retail and wholesale of pharmaceuticals.
